Chronic Obstructive Pulmonary Disease: Early Diagnosis for Better Outcomes

Silvija Zemnickienė
Pulmonology and Allergology Centre, Vilnius University Hospital Santaros Klinikos

Chronic obstructive pulmonary disease (COPD) is characterized by persistent, only partially reversible airflow limitation that progressively worsens over time. The disease is associated with an abnormal inflammatory response of the lungs to inhaled harmful particles or gases.

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is both preventable and treatable. Early diagnosis and timely intervention can slow the decline in lung function, helping patients maintain an active and independent life for longer.

Prevalence of COPD Worldwide and in Lithuania

COPD is one of the leading causes of illness and death worldwide and represents a growing economic and public health burden. It is currently the fourth leading cause of death globally.

The disease imposes substantial direct costs, including hospitalizations and medications, as well as indirect costs resulting from disability, reduced productivity, and premature mortality.

Although the exact global prevalence remains uncertain and varies between countries, it is estimated that approximately 200 million people are affected. Reported prevalence ranges from 7% to 19%, with estimates of 11.8% among men and 8.5% among women. COPD is most common in countries with high smoking rates.

Across Europe, approximately 200,000–300,000 people die from COPD each year. According to the World Health Organization (WHO), COPD accounted for 4.1% of male deaths and 2.4% of female deaths in Europe in 1997.

Many individuals live with COPD for years before dying prematurely from the disease or its complications. As populations age and exposure to risk factors continues over longer periods, the global burden of COPD is expected to increase further.

Comprehensive epidemiological data for Lithuania remain limited.

A 1999 study involving adults aged 25–64 years from five Lithuanian districts reported a COPD prevalence of 2.9%. Prevalence increased with age, reaching 10.4% among men aged 55–64 years.

According to the UK General Practice Research Database, approximately 40,569 people in Lithuania had COPD in 2005, representing around 3% of the adult population.

Approximately 1,000 people die from COPD each year in Lithuania. In 2007, COPD and asthma together accounted for 2.3% of all deaths in the country, almost half the proportion reported across Europe.

However, these figures are believed to underestimate the true burden of disease because COPD is frequently diagnosed only after symptoms become clinically apparent, usually in middle-aged or older adults, often after the age of 45.

Interestingly, countries with more accurate diagnosis and certification of causes of death often report higher COPD mortality. Sweden and Latvia illustrate this phenomenon. Although smoking prevalence is considerably higher in Latvia, proportional mortality from COPD is approximately 1%, compared with about 4% in Sweden. COPD is frequently recorded as a contributing rather than the primary cause of death, or omitted entirely from death certificates and health statistics.

Nevertheless, COPD remains one of the leading causes of mortality worldwide, including in Lithuania. It has been projected that by 2020, COPD would become the third leading cause of death globally.

How COPD Develops

COPD is a multifactorial disease affecting the large airways (bronchi), small airways (bronchioles), lung parenchyma, and pulmonary vasculature.

Chronic exposure to cigarette smoke and other harmful airborne substances triggers an exaggerated inflammatory response within the lungs. This leads to accumulation and activation of inflammatory cells, increased oxidative stress, and excessive protease activity, ultimately resulting in progressive destruction of lung tissue.

At the same time, excessive mucus production develops, impairing mucociliary clearance. Clinically, these changes manifest as chronic bronchitis, characterized by chronic cough and sputum production.

As the disease progresses, the small airways become narrowed, producing persistent airflow obstruction. Breathlessness gradually becomes the predominant symptom.

Hyperplasia of mucus-producing cells further increases mucus secretion, leading to continued sputum production. Progressive fibrosis, bronchiectasis, destruction of alveolar walls, emphysema, and air trapping further worsen airflow limitation and dyspnea.

Impaired mucus clearance and altered pulmonary immune defenses promote bacterial colonization of the airways. Common organisms include Streptococcus pneumoniae, β-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa. Increased bacterial colonization contributes to greater sputum production.

These pathological changes progressively impair pulmonary gas exchange, leading initially to hypoxemia and eventually pulmonary hypertension. As COPD advances, dysfunction extends beyond the lungs and affects multiple organ systems.

Clinical Presentation of COPD

COPD typically combines clinical features of chronic bronchitis, emphysema, and persistent airflow obstruction.

The hallmark symptoms are:

• progressive shortness of breath (dyspnea)
• chronic cough
• sputum production

Chronic cough is usually the earliest symptom. Initially intermittent, it gradually becomes a daily occurrence.

Following coughing episodes, patients often expectorate small amounts of thick, sticky sputum.

For most patients, however, progressive breathlessness is the symptom that ultimately prompts medical evaluation. Dyspnea is also the leading cause of disability and psychological distress in individuals with COPD.

As lung function declines, patients often reduce physical activity to avoid becoming breathless.

Risk factors for COPD include both environmental and individual factors.

Smoking remains the principal environmental risk factor, with approximately 80–90% of patients having a history of tobacco use.

Increasing attention is also being paid to occupational exposure to dust and chemical agents, as well as indoor and outdoor air pollution. Approximately 20% of patients with COPD have never smoked.

Less common individual risk factors include alpha-1 antitrypsin deficiency and a positive family history.

Accordingly, COPD should be considered in any patient presenting with chronic cough, sputum production, dyspnea, or relevant exposure to known risk factors.

COPD Is Often Diagnosed Too Late

Despite its characteristic symptoms, COPD is frequently diagnosed only after it has progressed to severe or very severe stages.

Because the disease develops gradually, many patients adapt to their declining physical capacity without recognizing the seriousness of their condition. Chronic cough and sputum production become accepted as part of everyday life, delaying medical consultation.

Many patients seek healthcare only after symptoms of respiratory failure develop, by which time irreversible lung damage has already occurred.

Late diagnosis remains a significant problem in Lithuania. Stable prevalence figures over many years suggest that opportunities for early detection are frequently missed.

Only an estimated 25–30% of individuals with COPD seek medical attention because of COPD-related symptoms.

Improving COPD outcomes in Lithuania depends heavily on primary care physicians recognizing the disease at an early stage and referring patients to pulmonologists when appropriate.

According to GOLD recommendations, early diagnosis and timely treatment are fundamental goals of COPD management. Prompt intervention can relieve symptoms, reduce the frequency and severity of exacerbations, improve overall health and exercise capacity, prevent complications, prolong survival, and help patients maintain a better quality of life.